Roberto Pili MD

Genitourinary Oncology, Hematologic Oncology

Robert Wallace Miller Professor of Oncology Professor of Medicine Professor of Urology Adjunct Professor of Pharmacology & Toxicology Robert Wallace Miller Professor of Oncology

Join to View Full Profile

45 Spindrift DrWilliamsville, NY 14221
Phone+1 716-422-5422
Fax+1 716-422-5420

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1994 - 1997
University of Cattolica del Sacro CuoreClass of 1989

Certifications & Licensure

NY State Medical License 2009 - 2026
IN State Medical License 2015 - 2021
MD State Medical License 1997 - 2011

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer Start of enrollment: 2002 Apr 01
Completed
Phase 2
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas Start of enrollment: 2004 Oct 01
Completed
Phase 1
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer Start of enrollment: 2005 May 01
Completed
Phase 2
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
Efficacy Study of ABR-215050 to Treat Prostate Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Oct 29
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2010 Feb 06
Completed
Phase 1
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery Start of enrollment: 2010 Apr 01
Terminated
Not Applicable
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2012 Feb 01
Terminated
Phase 1
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate Start of enrollment: 2010 Mar 01
Terminated
Phase 1, Phase 2
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2015 Jan 01
Completed
Phase 2
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma Start of enrollment: 2017 Jun 29
TERMINATED
PHASE1, PHASE2
Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer Start of enrollment: 2017 Dec 19
Completed
Not Applicable
High Dose IL 2 and Entinostat in RCC Start of enrollment: 2018 May 24
Active, not recruiting
Phase 2
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma Start of enrollment: 2018 Jul 31
TERMINATED
PHASE2
Join now to see all

Publications & Presentations

PubMed

Correlates of Perceived Illness Severity and Terminality in Advanced Lung and Prostate Cancer.
Michaela Di Palmo, Ekin Secinti, Ellen Krueger, Nasser H Hanna, Nabil Adra
Journal of Pain and Symptom Management. 2025-04-01
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advance...
Roberto Pili, David I Quinn, Nabil Adra, Theodore Logan, Sean Colligan
Cancer Medicine. 2025-04-01
Receiving immunotherapy for the treatment of advanced renal cell carcinoma is associated with higher burden of illness, coagulopathy, cardiac arrhythmia, and disparities.
Susan Eichhorn, Roberto Pili, Joel B Epstein, Richa Rajesh, Poolakkad S Satheeshkumar
Supportive Care in Cancer. 2025-03-15

Journal Articles

Phase 1 Trials of Anti-ENPP3 Antibody Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Roberto Pili, John A Thompson, Clinical Cancer Research
Dietary Protein Restriction Reprograms Tumor Associated Macrophages and Enhances Immunotherapy
Roberto Pili, MD, Clinical Cancer Research

Lectures

Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.
2019 ASCO Annual Meeting - 6/1/2019

Other

Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Roberto Pili, MD, Clinical Cancer Research
https://www.doximity.com/articles/8af396e1-337c-4e92-bdbb-e87959af489d
UpToDate, Wolters Kluwer Health - 2013-04-10

Authored Content

Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future PerspectivesSeptember 2018

Press Mentions

Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.March 27th, 2023
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.June 15th, 2022
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.June 15th, 2022
Join now to see all

Grant Support

Therapeutic targeting for translocation renal cell carcinomaSTATE UNIVERSITY OF NEW YORK AT BUFFALO2024–2029
Therapeutic targeting for translocation renal cell carcinomaSTATE UNIVERSITY OF NEW YORK AT BUFFALO2024–2029
Epigenetic Mechanisms of Drug Resistance in Renal Cell CarcinomaSTATE UNIVERSITY OF NEW YORK AT BUFFALO2021–2025